

Ray Therapeutics, a developer of optogenetic gene therapies for patients with blinding diseases, has raised $6 million in seed financing. The lead backer was 4Bio Capital.
Source: Press Release
Ray Therapeutics, a developer of optogenetic gene therapies for patients with blinding diseases, has raised $6 million in seed financing.
Ray Therapeutics, a developer of optogenetic gene therapies for patients with blinding diseases, has raised $6 million in seed financing. The lead backer was 4Bio Capital.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination